City of Hope
Dr. Dorff leads City of Hope’s joint effort with the Prostate Cancer Foundation to develop novel immune-based strategies for prostate cancer. Specifically, she leads an effort to develop chimeric antigen receptor (CAR) T cells – cells that are primed to target prostate cancer tissue. These strategies have been transformative in certain blood-based cancers. She is also engaging with TGen scientists Muhammad Murtaza, Ph.D., to investigate ctDNA as a biomarker, and Sarah Highlander, Ph.D., to study the role of the microbiome in earlier stage disease.
Dr. Dorff has assumed control of one of the largest clinical trial portfolios in genitourinary cancers, and treats patients with all types of genitourinary cancers, including testicular and penile cancer.
Abbvie (Individual(s) Involved: Self; Clinical Condition: oncology): Advisory Board; Astra Zeneca (Individual(s) Involved: Self; Clinical Condition: oncolog): Advisory Board; BAYER (Individual(s) Involved: Self; Clinical Condition: oncology): Advisory Board; Exelixis (Individual(s) Involved: Self; Clinical Condition: oncology): Advisory Board; Janssen Pharmaceuticals (Individual(s) Involved: Self; Clinical Condition: oncology): Advisory Board; Pfizer (Individual(s) Involved: Self; Clinical Condition: oncology): Advisory Board
Thursday, March 10, 2022
12:10 PM – 1:50 PM
Thursday, March 10, 2022
12:40 PM – 1:00 PM
Thursday, March 10, 2022
1:00 PM – 1:50 PM
Friday, March 11, 2022
2:15 PM – 3:35 PM
Friday, March 11, 2022
2:20 PM – 2:50 PM
Friday, March 11, 2022
2:50 PM – 3:10 PM